| A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML) (NCT07053020) | M.D. Anderson Cancer Center | 2027-12-01 |
| Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies (NCT07137481) | M.D. Anderson Cancer Center | 2027-02-28 |
| iCCARE Project #4: Grounded Theory Study of the Social Determinants of Migrant Health Factors Impacting Prostate Cancer Care and Survivorship Among Sub-Saharan African and Caribbean Immigrant Men Diagnosed With Prostate Cancer (NCT07105020) | M.D. Anderson Cancer Center | 2027-01-31 |
| A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA) (NCT07753824) | M.D. Anderson Cancer Center | 2027-01-16 |
| Phase 2 Trial Of S-531011 With RadScopal In Previously Treated Metastatic Colorectal Cancer (NCT07720115) | M.D. Anderson Cancer Center | 2027-01-07 |
| Dissemination Of Lung Cancer Screening Education Through Tobacco Quitlines (NCT07720141) | M.D. Anderson Cancer Center | 2027-01-01 |
| Chatbot Implementation In The Clinical Informed Consent Process (NCT07756515) | M.D. Anderson Cancer Center | 2027-01-01 |
| Development Of An Endometrial Cancer Educational Tool (NCT07739745) | M.D. Anderson Cancer Center | 2027-01-01 |
| Magnetic Sentinel Lymph Node Mapping in Gastric Cancer (NCT05038098) | M.D. Anderson Cancer Center | 2026-12-31 |
| A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia (NCT07674810) | M.D. Anderson Cancer Center | 2026-12-31 |
| Study Of KITE-753 in R/R B-Cell ALL (NCT07674823) | M.D. Anderson Cancer Center | 2026-12-31 |
| Phase 1 Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cell In Patients With Oral Premalignant Lesions (NCT07631013) | M.D. Anderson Cancer Center | 2026-12-31 |
| Wearable Device Tracked Recovery From Autologous Breast Reconstructive Surgery (NCT07631026) | M.D. Anderson Cancer Center | 2026-12-31 |
| Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma (NCT07164469) | M.D. Anderson Cancer Center | 2026-12-28 |
| Group-based Comprehensive Lifestyle Program for Women With Metastatic Breast Cancer (NCT07179809) | M.D. Anderson Cancer Center | 2026-12-28 |
| IGNITE-TX Phase III: (Identifying Individuals for Genetic Testing & Treatment) Intervention (NCT07318363) | M.D. Anderson Cancer Center | 2026-12-01 |
| Phase 2 Trial of G207 + 5 Gy Radiation for Children With High-Grade Gliomas (NCT07649070) | M.D. Anderson Cancer Center | 2026-11-30 |
| Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML (NCT07604233) | M.D. Anderson Cancer Center | 2026-11-30 |
| Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer (NCT07579221) | M.D. Anderson Cancer Center | 2026-11-30 |
| Pilot Study of Ivonescimab in Advanced/Metastatic Cutaneous Angiosarcoma (NCT07655570) | M.D. Anderson Cancer Center | 2026-11-30 |
| A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in Newly Diagnosed MDS/AML (≥ 10% Blasts) With TP53 Mutations (NCT07646821) | M.D. Anderson Cancer Center | 2026-11-27 |
| Oncologic Timely Palliative Care And Remote Monitoring With Electronic Assessments And Telehealth (ON-TARGET) (NCT07674797) | M.D. Anderson Cancer Center | 2026-11-22 |
| A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia (NCT07283640) | M.D. Anderson Cancer Center | 2026-11-18 |
| Nasal Inhalation of Isopropyl Alcohol for the Treatment of Nausea in Patients With Cancer (NCT04181463) | M.D. Anderson Cancer Center | 2026-11-05 |
| Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial (NCT07610525) | M.D. Anderson Cancer Center | 2026-11-05 |
| NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy (NCT07227909) | M.D. Anderson Cancer Center | 2026-11-04 |
| Creating Opportunities For Personal Empowerment (COPE) In Women With Breast Cancer During First-Line Therapy: A Pilot Randomized Controlled Trial (NCT07610499) | M.D. Anderson Cancer Center | 2026-10-30 |
| A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma (NCT07579208) | M.D. Anderson Cancer Center | 2026-10-24 |
| A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy (NCT07633756) | M.D. Anderson Cancer Center | 2026-10-19 |
| ACT-GEN (Adherence And Care Tracking In GENetic Cancer Syndromes) (NCT07565467) | M.D. Anderson Cancer Center | 2026-10-08 |
| Phase 2 Study Of Imetelstat for Patient With Myelodysplastic/Myeloproliferative Neoplasms (NCT07549451) | M.D. Anderson Cancer Center | 2026-10-08 |
| Phase I Study Of PLM-102 In Patients With Relapsed And Refractory Acute Myeloid Leukemia (NCT07549464) | M.D. Anderson Cancer Center | 2026-10-01 |
| Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL (NCT07551583) | M.D. Anderson Cancer Center | 2026-10-01 |
| A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma (NCT07527169) | M.D. Anderson Cancer Center | 2026-10-01 |
| Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers (NCT07553390) | M.D. Anderson Cancer Center | 2026-10-01 |
| OCRA Distress & Unmet Needs (NCT07591623) | M.D. Anderson Cancer Center | 2026-10-01 |
| Decision Support Tool to Enhance Germline Genetic Testing for Patients With Prostate Cancer (NCT07377006) | M.D. Anderson Cancer Center | 2026-10-01 |
| Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer (NCT07470489) | M.D. Anderson Cancer Center | 2026-09-30 |
| A Phase 1 Trial Of Safety And Initial Efficacy Of Vagal Nerve Blockade For Cancer-Induced Cachexia In Patients With Metastatic Pancreatic Adenocarcinoma (NCT07700212) | M.D. Anderson Cancer Center | 2026-09-30 |
| Phase 2 Trial Of Sacituzumab Tirumotecan For Treatment Of Refractory Metastatic Or Unresectable Squamous Cell Carcinoma Of The Anus/Rectum (NCT07511023) | M.D. Anderson Cancer Center | 2026-09-25 |
| Evaluating Intermittent Fasting In Individuals At High Risk ForPancreatic Cancer Undergoing Screening (NCT07513116) | M.D. Anderson Cancer Center | 2026-09-17 |
| Checkpoint Inhibitor Associated Diabetes Mellitus: Early Recognition and Treatment (CERT) Project: A Pilot Study (NCT07257068) | M.D. Anderson Cancer Center | 2026-09-14 |
| RISE: Reducing Cancer and HIV Stigma Through Empowerment (NCT07728370) | M.D. Anderson Cancer Center | 2026-09-01 |
| Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum (NCT07509008) | M.D. Anderson Cancer Center | 2026-09-01 |
| PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma (NCT07511036) | M.D. Anderson Cancer Center | 2026-09-01 |
| A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL) (NCT07508995) | M.D. Anderson Cancer Center | 2026-09-01 |
| Phase 1 Study Of Intrathecal Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells For Patients With Leptomeningeal Melanoma (NCT07414979) | M.D. Anderson Cancer Center | 2026-08-31 |
| Improving Processes of Cancer Care Delivery at a Comprehensive Cancer Center (NCT05095948) | M.D. Anderson Cancer Center | 2026-08-30 |
| Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL) (NCT07178912) | M.D. Anderson Cancer Center | 2026-08-27 |
| A Study to Evaluate the Safety and Efficacy of Intracranial Venous Blood Sampling for Liquid Biopsy in the Diagnosis of Brain Cancers (NCT07467109) | M.D. Anderson Cancer Center | 2026-08-19 |
| Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits: a Randomized Controlled Trial (EHR Study #3) (NCT07089953) | M.D. Anderson Cancer Center | 2026-08-03 |
| PREDICTT Clinical Trial: Prospective Evaluation Of Pressure-Enabled Delivery And Alterations In CT-Based Tumor-To-Normal Liver Ratio And Tumor Dose Using The Trinav Infusion System (NCT07444645) | M.D. Anderson Cancer Center | 2026-08-01 |
| Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (NCT07269470) | M.D. Anderson Cancer Center | 2026-07-13 |
| Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD (NCT07566364) | M.D. Anderson Cancer Center | 2026-07-09 |
| Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma (NCT07564232) | M.D. Anderson Cancer Center | 2026-07-02 |
| A Randomized Trial Comparing Routine Use of the ActiValve to Standard Voice Prostheses (NCT07369050) | M.D. Anderson Cancer Center | 2026-07-01 |
| A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas (NCT07444619) | M.D. Anderson Cancer Center | 2026-06-12 |
| Optimizing Contrast Dose and Scanning Parameters for Detection of Leptomeningeal Disease (NCT07415018) | M.D. Anderson Cancer Center | 2026-06-10 |
| ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer (NCT07318389) | M.D. Anderson Cancer Center | 2026-06-10 |
| Immediate Lymphatic Reconstruction After Lymphadenectomy in Melanoma Patients: a Parallel Cohort Pilot Study (NCT06887205) | M.D. Anderson Cancer Center | 2026-06-10 |
| Prospective Observational Study of Outcomes After Gemcitabine, Docetaxel, Melphalan, and Carboplatin With Autologous Stem Cell Transplantation in Pediatric Relapsed/Refractory Germ Cell Tumors (NCT07662018) | M.D. Anderson Cancer Center | 2026-06-05 |
| Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma (NCT07513129) | M.D. Anderson Cancer Center | 2026-06-05 |
| Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma (NCT07438626) | M.D. Anderson Cancer Center | 2026-06-01 |
| Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies (NCT07444632) | M.D. Anderson Cancer Center | 2026-05-28 |
| Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia (NCT07411586) | M.D. Anderson Cancer Center | 2026-05-28 |
| OBSERVE: A Pilot Study Of Omission Of Brain Metastasis Stereotactic Radiosurgery Following Resection With CNS-Active Systemic Therapy (NCT07655583) | M.D. Anderson Cancer Center | 2026-05-27 |
| Efforts to Increase Representation in Prostate Cancer Clinical Trials at Lyndon B. Johnson Hospital (NCT07591701) | M.D. Anderson Cancer Center | 2026-05-26 |
| TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer (NCT07377526) | M.D. Anderson Cancer Center | 2026-05-26 |
| Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML (NCT07508982) | M.D. Anderson Cancer Center | 2026-05-22 |
| A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and Relapsed /Refractory Pediatric Acute Leukemia Patients (NCT07052994) | M.D. Anderson Cancer Center | 2026-05-21 |
| Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer (NCT07500298) | M.D. Anderson Cancer Center | 2026-05-20 |
| A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer (NCT07283705) | M.D. Anderson Cancer Center | 2026-05-18 |
| Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial (NCT07382726) | M.D. Anderson Cancer Center | 2026-05-15 |
| Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer (NCT07318324) | M.D. Anderson Cancer Center | 2026-05-13 |
| Baseline Anxiety Trajectories in Pediatric Radiation Therapy Observational Cohort (NCT07575815) | M.D. Anderson Cancer Center | 2026-05-06 |
| Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia (NCT07311746) | M.D. Anderson Cancer Center | 2026-04-28 |
| A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (NCT07428486) | M.D. Anderson Cancer Center | 2026-04-27 |
| Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer (NCT07415005) | M.D. Anderson Cancer Center | 2026-04-24 |
| Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation (NCT07076498) | M.D. Anderson Cancer Center | 2026-04-23 |
| Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial") (NCT07411599) | M.D. Anderson Cancer Center | 2026-04-20 |
| The Impact Of A Patient Support Community On Patients With Neuroendocrine Cervical Cancer: NECC Peer Support (NCT07532954) | M.D. Anderson Cancer Center | 2026-04-13 |
| Molecular Surveillance In Early Breast Cancer Using The Tumor-Informed ctDNA Assay Myriad Genetics Precise MRD Test; A Prospective Observational Multicenter Study (The MRD Molecular Surveillance Study) (NCT07475923) | M.D. Anderson Cancer Center | 2026-04-09 |
| DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins (NCT07298083) | M.D. Anderson Cancer Center | 2026-04-02 |
| Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study (NCT07257055) | M.D. Anderson Cancer Center | 2026-04-01 |
| Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigating Radiation-response and Toxicity (NCT06909201) | M.D. Anderson Cancer Center | 2026-03-31 |
| A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD" (NCT07382739) | M.D. Anderson Cancer Center | 2026-03-31 |
| Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow Function (NCT07169825) | M.D. Anderson Cancer Center | 2026-03-30 |
| NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer (NCT07224152) | M.D. Anderson Cancer Center | 2026-03-27 |
| A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK) (NCT07401875) | M.D. Anderson Cancer Center | 2026-03-24 |
| Interactive Design of Patient-Specific Molds for Tissue Shaping (NCT06711965) | M.D. Anderson Cancer Center | 2026-03-02 |
| Abbreviated Biparametric MRI (RSI + T2WI) for Prostate Cancer Detection: Correlation With Histopathology (NCT05046782) | M.D. Anderson Cancer Center | 2026-02-28 |
| Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma (NCT07283679) | M.D. Anderson Cancer Center | 2026-02-24 |
| Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients (NCT06807593) | M.D. Anderson Cancer Center | 2026-02-24 |
| Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms (NCT07382817) | M.D. Anderson Cancer Center | 2026-02-18 |
| Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the Primary Prevention of Endometrial Cancer (NCT07382583) | M.D. Anderson Cancer Center | 2026-02-12 |
| Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss (NCT07382544) | M.D. Anderson Cancer Center | 2026-02-12 |
| Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study (NCT07187869) | M.D. Anderson Cancer Center | 2026-02-12 |
| Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma (NCT07218315) | M.D. Anderson Cancer Center | 2026-02-11 |
| Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHD (NCT07127926) | M.D. Anderson Cancer Center | 2026-02-09 |
| Facilitators and Barriers to Cancer Treatment Among Texas Residents (NCT07105046) | M.D. Anderson Cancer Center | 2026-01-31 |